HCC patients from IMbrave150 and GO30140 with a response to atezolizumab plus bevacizumab also showed a higher SPP1 + SIRPα + macrophages signature score at baseline (Fig. 5K). The gene discussed is SIRPA; the disease is hepatocellular carcinoma.